Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR1 | P03372 | 1/20 | 0.36 |
| ▸ | AXL | P30530 | 1/20 | 0.36 |
| ▸ | TYRO3 | Q06418 | 1/20 | 0.36 |
| ▸ | MERTK | Q12866 | 1/20 | 0.36 |
| ▸ | PDE4A | P27815 | 12/20 | 0.34 |
| ▸ | PDE4B | Q07343 | 12/20 | 0.34 |
| ▸ | PDE4C | Q08493 | 12/20 | 0.34 |
| ▸ | PDE4D | Q08499 | 12/20 | 0.34 |
| ▸ | TEAD1 | P28347 | 1/20 | 0.33 |
| ▸ | TEAD4 | Q15561 | 1/20 | 0.33 |
| ▸ | TEAD2 | Q15562 | 1/20 | 0.33 |
| ▸ | LRRK2 | Q5S007 | 2/20 | 0.32 |
| ▸ | PTGDR2 | Q9Y5Y4 | 2/20 | 0.32 |
| ▸ | CMKLR1 | Q99788 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6794334 | 1.00 | ESR1 (0.36) | ESR1AXLTYRO3MERTKPDE4A | |
| SCHEMBL6791320 | 0.99 | AXL (0.36) | ESR1AXLTYRO3MERTKPDE4A | |
| SCHEMBL6791328 | 0.99 | AXL (0.36) | ESR1AXLTYRO3MERTKPDE4A | |
| SCHEMBL6802477 | 0.97 | AXL (0.36) | ESR1AXLTYRO3MERTKPDE4A | |
| SCHEMBL6796868 | 0.97 | AXL (0.36) | ESR1AXLTYRO3MERTKPDE4A | |
| SCHEMBL6796863 | 0.97 | AXL (0.36) | ESR1AXLTYRO3MERTKPDE4A | |
| SCHEMBL6182562 | 0.90 | LRRK2 (0.35) | ESR1AXLTYRO3MERTKPDE4A | |
| SCHEMBL6798314 | 0.90 | LRRK2 (0.35) | ESR1AXLTYRO3MERTKPDE4A | |
| SCHEMBL6791379 | 0.90 | AXL (0.37) | ESR1AXLTYRO3MERTKPDE4A | |
| SCHEMBL6791374 | 0.90 | AXL (0.37) | ESR1AXLTYRO3MERTKPDE4A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6716978-B2 | FOR THERAPY AND PROHYLAXIS OF INFLAMMATORY DISEASES INCLUDING JOINT INFLAMMATION, CROHN'S DISEASE, AND INFLAMMATORY BOWEL DISEASE; RESPIRATORY DISEASES SUCH AS CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) INCLUDING ASTHMA, CHRONIC BRONCHITIS | PFIZER INC | 2004-04-06 | — | — | US | claimed |
| US-20030176421-A1 | PROKINETIC AGENTS FOR TREATING GASTRIC HYPOMOTILITY AND RELATED DISORDERS | WATSON JOHN W (US) | 2003-09-18 | — | — | US | claimed |
| US-20030158189-A1 | Therapeutically active compounds based on indazole bioisostere replacement of catechol in PDE4 inhibitors | MARFAT ANTHONY (US) | 2003-08-21 | — | — | US | claimed |
| US-20020058687-A1 | THERAPEUTICALLY ACTIVE COMPOUNDS BASED ON INDAZOLE BIOISOSTERE REPLACEMENT OF CATECHOL IN PDE4 INHIBITORS | MARFAT ANTHONY (US) | 2002-05-16 | — | — | US | claimed |
| US-6211222-B1 | Substituted indazole derivatives and related compounds | PFIZER INC | 2001-04-03 | — | — | US | claimed |
| EP-1040829-A2 | Prokinetic agents for treating gastric hypomotility and related disorders | PFIZER INC. (US) | 2000-10-04 | — | — | EP | claimed |
| US-6716978-B2 | FOR THERAPY AND PROHYLAXIS OF INFLAMMATORY DISEASES INCLUDING JOINT INFLAMMATION, CROHN'S DISEASE, AND INFLAMMATORY BOWEL DISEASE; RESPIRATORY DISEASES SUCH AS CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) INCLUDING ASTHMA, CHRONIC BRONCHITIS | PFIZER INC | 2004-04-06 | — | — | US | disclosed |
| US-20030176421-A1 | PROKINETIC AGENTS FOR TREATING GASTRIC HYPOMOTILITY AND RELATED DISORDERS | WATSON JOHN W (US) | 2003-09-18 | — | — | US | disclosed |
| US-20030158189-A1 | Therapeutically active compounds based on indazole bioisostere replacement of catechol in PDE4 inhibitors | MARFAT ANTHONY (US) | 2003-08-21 | — | — | US | disclosed |
| US-6391872-B1 | SENSITIVE TO ADRENERGIC ANTAGONIST | PFIZER INC | 2002-05-21 | — | — | US | disclosed |
| US-20020058687-A1 | THERAPEUTICALLY ACTIVE COMPOUNDS BASED ON INDAZOLE BIOISOSTERE REPLACEMENT OF CATECHOL IN PDE4 INHIBITORS | MARFAT ANTHONY (US) | 2002-05-16 | — | — | US | disclosed |
| US-6211222-B1 | Substituted indazole derivatives and related compounds | PFIZER INC | 2001-04-03 | — | — | US | disclosed |
| EP-1040829-A2 | Prokinetic agents for treating gastric hypomotility and related disorders | PFIZER INC. (US) | 2000-10-04 | — | — | EP | disclosed |
| US-6127398-A | Substituted indazole derivatives and related compounds | PFIZER INC (US) | 2000-10-03 | — | — | US | disclosed |
| EP-1028946-A1 | INDAZOLE BIOISOSTERE REPLACEMENT OF CATECHOL IN THERAPEUTICALLY ACTIVE COMPOUNDS | Pfizer Products Inc. (US) | 2000-08-23 | — | — | EP | disclosed |
| WO-1999023077-A1 | INDAZOLE BIOISOSTERE REPLACEMENT OF CATECHOL IN THERAPEUTICALLY ACTIVE COMPOUNDS | PFIZER PRODUCTS INC. (US) | 1999-05-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030158189-A1 | Therapeutically active compounds based on indazole bioisostere replacement of catechol in PDE4 inhibitors | PDE4B, PDE3B, PDE4A | ESR1 1494/4885AXL 4238/4885TYRO3 3236/4885 |
| US-20030176421-A1 | PROKINETIC AGENTS FOR TREATING GASTRIC HYPOMOTILITY AND RELATED DISORDERS | OPRM1, OPRK1, OPRD1 | ESR1 4624/4885AXL 2927/4885TYRO3 4192/4885 |
| US-20020058687-A1 | THERAPEUTICALLY ACTIVE COMPOUNDS BASED ON INDAZOLE BIOISOSTERE REPLACEMENT OF CATECHOL IN PDE4 INHIBITORS | PDE3B, ALPI, PDE4B | ESR1 1600/4885AXL 4423/4885TYRO3 3918/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.